Alopecia areata – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Alopecia areata – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years https://clinicaltrials.eu/trial/study-of-ritlecitinib-for-treating-severe-alopecia-areata-in-children-aged-6-to-under-12-years/ Thu, 30 Apr 2026 13:08:06 +0000 https://clinicaltrials.eu/trial/study-of-ritlecitinib-for-treating-severe-alopecia-areata-in-children-aged-6-to-under-12-years/ This clinical trial focuses on children aged 6 to under 12 years who have severe alopecia areata, a condition that causes hair loss on the scalp. The study aims to evaluate how well a medication called ritlecitinib (also known as PF-06651600) works compared to placebo in helping regrow lost scalp hair in children with this condition.

The study medication ritlecitinib comes in the form of hard capsules and will be taken by mouth. Participants will receive either ritlecitinib at doses of 30 mg or 50 mg per day, or a placebo. The treatment period will last for 24 weeks, which is approximately 6 months.

During the study, researchers will monitor how well the medication works by measuring hair regrowth on the scalp. They will also track any side effects that may occur. The study will collect information about how the treatment affects the participants’ daily activities and emotional well-being. Blood samples will be taken to measure the amount of medication in the body at specific times during the study.

]]> A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-lad603-in-adults-with-severe-to-very-severe-alopecia-areata/ Wed, 29 Apr 2026 15:09:38 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-lad603-in-adults-with-severe-to-very-severe-alopecia-areata/ This study focuses on individuals living with Alopecia areata, an autoimmune condition that causes hair loss in patches on the scalp or body. The purpose of the study is to evaluate the efficacy and safety of a medication called LAD603 in adults experiencing severe to very severe forms of this condition. LAD603 is administered as a subcutaneous injection, which is a method where the medicine is delivered through a small needle into the fatty layer of the skin just under the surface.

Participants in this trial will be randomly assigned to receive either LAD603 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which specific treatment is being administered during the process. This approach helps ensure that the results are measured objectively. Over the course of the study, the effects of the medication will be monitored to determine how well it works compared to the placebo.

]]> A study comparing how ritlecitinib capsules work when sprinkled on food versus swallowed whole and with or without food in healthy adults https://clinicaltrials.eu/trial/a-study-comparing-how-ritlecitinib-capsules-work-when-sprinkled-on-food-versus-swallowed-whole-and-with-or-without-food-in-healthy-adults/ Wed, 29 Apr 2026 15:08:27 +0000 https://clinicaltrials.eu/trial/a-study-comparing-how-ritlecitinib-capsules-work-when-sprinkled-on-food-versus-swallowed-whole-and-with-or-without-food-in-healthy-adults/ This study involves Ritlecitinib, a medicine being tested for several conditions including Alopecia Areata, which is a condition that causes hair loss in patches, Rheumatoid Arthritis, which is a disease where the body’s immune system attacks the joints causing pain and swelling, Vitiligo, which is a condition that causes loss of skin color in patches, Ulcerative Colitis, which is a disease that causes inflammation and sores in the lining of the large intestine, and Crohn’s Disease, which is a condition that causes inflammation of the digestive tract. The medicine comes in the form of a hard capsule that can be taken by mouth. The study will look at how the body absorbs the medicine when the capsule contents are sprinkled on different foods compared to when the capsule is swallowed whole.

The purpose of this study is to measure how much of the medicine gets into the bloodstream when the capsule is opened and sprinkled on applesauce, strawberry jam, or yoghurt compared to swallowing the capsule whole without food, and also to see how eating food affects the amount of medicine that gets into the bloodstream when the capsule is swallowed whole. This information is important for understanding different ways the medicine can be taken, especially for people who may have difficulty swallowing capsules. The study will involve healthy adult participants who will receive a 30 mg dose of the medicine in different ways during the study.

Participants will take part in a study where they will receive the medicine in different forms on different occasions, allowing researchers to compare how the body processes the medicine under various conditions. Blood samples will be collected to measure the amount of medicine in the bloodstream over time. The study will monitor participants for any unwanted effects that may occur during the treatment period.

]]> Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031 https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-ritlecitinib-in-children-with-severe-alopecia-areata-who-completed-previous-trials-b7981027-or-b7981031/ Wed, 29 Apr 2026 15:07:27 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-ritlecitinib-in-children-with-severe-alopecia-areata-who-completed-previous-trials-b7981027-or-b7981031/ This clinical trial studies the long-term effects of ritlecitinib in people with alopecia areata, a condition that causes hair loss. The study includes patients with severe forms of the disease, including alopecia totalis (complete loss of scalp hair) and alopecia universalis (loss of all body hair), who have previously participated in related studies.

The study uses ritlecitinib (also known as PF-06651600) in the form of hard capsules that are taken by mouth. Participants will receive either ritlecitinib at doses of 30 mg or 50 mg daily, or placebo. The treatment will continue for up to 36 months to evaluate how safe and effective the medication is over an extended period.

During the study, doctors will monitor hair growth on the scalp, eyebrows, and eyelashes. They will also track any changes in the participants’ quality of life, emotional well-being, and behavior. The main focus is on checking the safety of the treatment and measuring how well it works in managing hair loss caused by alopecia areata.

]]> Study on Etrasimod Arginine for Patients with Ulcerative Colitis, Alopecia Areata, Atopic Dermatitis, and Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-etrasimod-arginine-for-patients-with-ulcerative-colitis-alopecia-areata-atopic-dermatitis-and-eosinophilic-esophagitis/ Wed, 29 Apr 2026 15:05:28 +0000 https://clinicaltrials.eu/trial/study-on-etrasimod-arginine-for-patients-with-ulcerative-colitis-alopecia-areata-atopic-dermatitis-and-eosinophilic-esophagitis/ This clinical trial is focused on studying a group of diseases known as immune-mediated inflammatory disorders. These include conditions like ulcerative colitis, alopecia areata, atopic dermatitis, and eosinophilic esophagitis. The study is testing a medication called Etrasimod Arginine, which is being developed by Pfizer Inc. The medication is being tested in the form of mini tablets, which are small tablets that can be mixed with different foods or water.

The purpose of the study is to learn more about how the body absorbs the Etrasimod Arginine mini tablets when they are mixed with different foods like applesauce, chocolate pudding, yogurt, or just water. The study will also look at how the mini tablets taste when mixed with these foods. Participants in the study will take a single dose of the mini tablets in different forms, and researchers will compare how the body absorbs the medication in each case.

The study involves healthy adult participants who will take part in a series of tests to see how the medication is absorbed and how it tastes. The study will help researchers understand the best way to deliver the medication to patients in the future. Participants will be monitored for any side effects and will provide feedback on the taste and feel of the mini tablets. This information will be used to improve the medication for future use in treating the diseases being studied.

]]> Study on the Effects of Ritlecitinib in Patients Aged 12 and Older with Alopecia Areata https://clinicaltrials.eu/trial/study-on-the-effects-of-ritlecitinib-in-patients-aged-12-and-older-with-alopecia-areata/ Wed, 29 Apr 2026 15:05:12 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ritlecitinib-in-patients-aged-12-and-older-with-alopecia-areata/ This clinical trial is focused on studying the effects of a medication called Ritlecitinib Tosilate in people aged 12 and older who have Alopecia Areata. Alopecia Areata is a condition that causes hair loss, often in patches, on the scalp and other parts of the body. The study will test two different doses of Ritlecitinib Tosilate, 50 mg and 100 mg, taken once daily. The purpose of the study is to see how effective these doses are in helping hair regrow on the scalp.

Participants in the study will be randomly assigned to receive either Ritlecitinib Tosilate or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of 48 weeks, during which participants will take the medication daily. Throughout the study, participants will have regular check-ups to monitor their progress and any changes in their hair growth.

The main goal is to compare the effects of the 100 mg dose of Ritlecitinib Tosilate with the placebo in terms of hair regrowth. The study will also look at how participants feel about their hair growth and any improvements they notice. This research aims to provide more information about the safety and effectiveness of Ritlecitinib Tosilate for treating Alopecia Areata.

]]> Study of amlitelimab injection compared to placebo for adults with severe alopecia areata (hair loss) https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-amlitelimab-for-adults-with-severe-alopecia-areata/ Wed, 29 Apr 2026 15:00:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-amlitelimab-for-adults-with-severe-alopecia-areata/ This study focuses on alopecia areata, a condition that causes severe hair loss on the scalp. The research evaluates a new medication called amlitelimab, which is given as an injection under the skin (subcutaneous injection). The purpose is to determine how well amlitelimab works in helping regrow hair in adults who have lost 50% or more of their scalp hair.

The study compares amlitelimab to placebo in people with severe hair loss that has lasted more than 6 months. The treatment involves receiving injections over a period of 36 weeks. The medication comes in the form of a solution for injection in pre-filled syringe, making it easier to administer.

During the study, doctors will measure how much hair grows back on participants’ scalps. They will also look at hair regrowth in eyebrows and eyelashes, and monitor how participants feel about their improvement. The study will track any side effects that may occur during the treatment period to ensure the medication’s safety.

]]> Study on Rezpegaldesleukin for Treating Severe Alopecia Areata in Adults https://clinicaltrials.eu/trial/study-on-rezpegaldesleukin-for-treating-severe-alopecia-areata-in-adults/ Wed, 29 Apr 2026 14:57:42 +0000 https://clinicaltrials.eu/trial/study-on-rezpegaldesleukin-for-treating-severe-alopecia-areata-in-adults/ This clinical trial is focused on studying a condition called Alopecia Areata, which is a type of hair loss that can be severe or very severe. The study is testing a new treatment called Rezpegaldesleukin, also known by its code name NKTR-358. This treatment is a special form of a protein that is injected under the skin. The trial will compare the effects of Rezpegaldesleukin with a placebo to see how well it works in reducing hair loss.

The purpose of the study is to evaluate the effectiveness and safety of Rezpegaldesleukin in treating severe to very severe Alopecia Areata in adults. Participants in the study will receive either the new treatment or a placebo. The study will last for several weeks, with regular check-ups to monitor progress. The main goal is to see if there is a reduction in hair loss by the 36th week of the study.

Throughout the study, participants will be asked to attend scheduled visits and complete questionnaires about their condition. The study aims to provide valuable information on whether Rezpegaldesleukin can be a helpful treatment for those suffering from severe hair loss due to Alopecia Areata.

]]> Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-upadacitinib-for-adults-and-adolescents-with-severe-alopecia-areata/ Wed, 29 Apr 2026 14:47:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-upadacitinib-for-adults-and-adolescents-with-severe-alopecia-areata-2/ This clinical trial is focused on studying the condition known as Alopecia Areata, which is a type of hair loss that can affect the scalp and other parts of the body. The study will evaluate the safety and effectiveness of a medication called Upadacitinib, which is taken as a modified-release tablet. This means the tablet is designed to release the medication slowly over time. The study will compare the effects of taking Upadacitinib at different doses to a placebo, which is a tablet that does not contain the active medication.

The purpose of the study is to assess how well Upadacitinib works in reducing the signs and symptoms of severe Alopecia Areata in both adults and adolescents. Participants will be randomly assigned to receive either Upadacitinib or a placebo. The study will be conducted in several phases. Initially, participants will take the medication or placebo for a period of 24 weeks. After this period, some participants may continue in an extended phase of the study for up to 160 weeks, where the long-term effects and safety of the medication will be further evaluated.

Throughout the study, participants will be monitored to see how their condition responds to the treatment. The main goal is to determine if Upadacitinib can help reduce hair loss and improve hair regrowth in those with severe Alopecia Areata. The study will also look at the safety of the medication and how well it is tolerated by participants over time. This research aims to provide valuable information on the potential benefits of Upadacitinib for individuals affected by this condition.

]]> Long-Term Study of Ritlecitinib Tosilate for Adults and Adolescents with Alopecia Areata https://clinicaltrials.eu/trial/long-term-study-of-ritlecitinib-tosilate-for-adults-and-adolescents-with-alopecia-areata/ Wed, 29 Apr 2026 14:28:31 +0000 https://clinicaltrials.eu/trial/long-term-study-of-ritlecitinib-tosilate-for-adults-and-adolescents-with-alopecia-areata/ This clinical trial is focused on studying the long-term safety and effectiveness of a medication called Ritlecitinib Tosilate for treating a condition known as Alopecia Areata. Alopecia Areata is a disease that causes hair loss, often in patches, and can affect both adults and adolescents. The medication being tested, Ritlecitinib Tosilate, is taken orally in the form of capsules or tablets and works as a Janus Kinase 3 inhibitor, which is a type of treatment that targets specific pathways in the body to help manage the condition.

The purpose of this study is to evaluate how safe and tolerable Ritlecitinib Tosilate is for people with Alopecia Areata over a long period. Participants in the study will take the medication and attend regular visits to monitor their health and any changes in their condition. The study will track any side effects or adverse events that may occur, as well as any improvements in hair growth or other symptoms related to Alopecia Areata.

Throughout the study, participants will be asked to follow a treatment plan and attend scheduled visits for check-ups and tests. The study aims to provide valuable information about the long-term use of Ritlecitinib Tosilate in managing Alopecia Areata, helping to determine its potential as a treatment option for this condition.

]]> Study on Baricitinib for Treating Children Aged 6 to 17 with Alopecia Areata https://clinicaltrials.eu/trial/study-on-baricitinib-for-treating-children-aged-6-to-17-with-alopecia-areata/ Wed, 29 Apr 2026 14:23:23 +0000 https://clinicaltrials.eu/trial/study-on-baricitinib-for-treating-children-aged-6-to-17-with-alopecia-areata/ This clinical trial is focused on studying alopecia areata, a condition that causes hair loss, in children aged 6 to less than 18 years. The treatment being tested is called baricitinib, which is taken orally in the form of a tablet or oral suspension. The study aims to determine if different doses of baricitinib are more effective than a placebo in treating children with this condition.

Participants in the study will receive either a high dose or a low dose of baricitinib, or a placebo, over a period of time. The study will monitor the effects of the treatment on hair regrowth and assess the safety of baricitinib in children. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

The main goal of the study is to see if baricitinib can help reduce the severity of hair loss in children with alopecia areata. The study will track the percentage of participants who achieve a significant improvement in their condition. This research is important for understanding how effective baricitinib is in treating alopecia areata in a younger population and could lead to better treatment options in the future.

]]>